Caraco settles patent suit over cancer generic
DETROIT A generic drug maker announced Monday that it had settled patent litigation over a generic version of a cancer drug.
Caraco Pharmaceutical Labs said it reached a settlement with MedImmune over a generic version of the drug Ethyol (amifostine). MedImmune had filed the suit in the U.S. District Court for the District of Maryland.
Under the settlement, MedImmune granted Caraco a license to certain patents that permit Caraco to continue marketing its generic version of Ethyol in the United States.
GSK: Rheumatoid arthritis treatment meets trial goals
LONDON A late-stage clinical trial of a biotech drug for rheumatoid arthritis has met its goals, the drug’s developers announced Wednesday.
British drug maker GlaxoSmithKline and Danish drug maker Genmab announced that patients in a phase 3 trial taking ofatumumab experienced a 20% improvement in the number of swollen and tender joints, as the companies expected.
In the 260-patient study, the 129 patients taking ofatumumab had a 50% response rate, compared to 27% of those taking placebo. The companies also said there were no unexpected safety problems, but 5% of patients experienced rash, hives, throat irritation and other side effects.
“We have always believed in ofatumumab’s potential to make a difference in patients’ lives,” Genmab CEO Lisa Drakeman said in a statement. “We are pleased with the results of this study, supporting the further investigation of this antibody’s promise in the treatment of RA.”
Medarex reports narrowed loss, nearly doubled revenue for Q2
PRINCETON, N.J. Biotech drug maker Medarex reported a less severe drop in second-quarter loss, while its revenue almost doubled from last year.
The Princeton, N.J.-based Medarex reported losses of $29.2 million compared with a loss of $53.1 million in the same quarter last year.
This year’s revenue was up 96% from last year’s $10 million to $19.5 million.
New York-based Bristol-Myers Squibb, the maker of blood thinner Plavix, put forth $2.1 billion to acquire Medarex.